Discover how mirdametinib, a next-generation MEK1/2 inhibitor originally developed for MAPK-driven tumors, is emerging as a promising tool to modulate ERK signaling, improve synaptic plasticity, and potentially treat treatment-resistant depression beyond traditional monoamine-based antidepressants.
Discover how Novartis’s investigational NMDA modulator MIJ821 offers rapid antidepressant effects for treatment‑resistant depression with fewer dissociative, cognitive, and cardiovascular side effects than ketamine and esketamine.